Clínica Baviera, S.A. (BME:CBAV)
Spain · Delayed Price · Currency is EUR 56.20
-0.40 (-0.71%)
Sep 16, 2026, 5:35 PM CET
Clínica Baviera Ratios and Metrics
Market cap in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 907 | 796 | 499 | 375 | 284 | 346 | |
Market Cap Growth | 25.00% | 59.55% | 33.02% | 31.81% | -17.69% | 50.35% |
Enterprise Value | 928 | 819 | 529 | 376 | 286 | 360 |
Last Close Price | 56.60 | 48.64 | 29.63 | 20.97 | 15.37 | 17.97 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 19.72 | 18.92 | 12.41 | 10.42 | 9.64 | 12.62 |
Forward PE | - | 11.01 | 11.01 | 11.01 | 9.86 | 23.87 |
PS Ratio | 2.83 | 2.61 | 1.88 | 1.65 | 1.43 | 2.00 |
PB Ratio | 8.09 | 7.17 | 5.07 | 4.06 | 4.16 | 6.24 |
P/TBV Ratio | 12.88 | 11.39 | 8.43 | 5.09 | 5.44 | 8.86 |
P/FCF Ratio | 19.59 | 16.99 | 13.86 | 10.67 | 7.23 | 9.53 |
P/OCF Ratio | 11.76 | 10.36 | 7.98 | 6.49 | 5.33 | 7.38 |
PEG Ratio | - | 2.65 | 2.65 | 2.65 | 2.47 | 2.19 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.89 | 2.69 | 1.99 | 1.66 | 1.44 | 2.08 |
EV/EBITDA Ratio | 10.45 | 9.90 | 7.00 | 5.66 | 5.04 | 6.75 |
EV/EBIT Ratio | 14.36 | 13.51 | 9.51 | 7.52 | 6.82 | 9.13 |
EV/FCF Ratio | 20.03 | 17.50 | 14.70 | 10.71 | 7.27 | 9.93 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.64 | 0.62 | 0.62 | 0.51 | 0.70 | 0.93 |
Debt / EBITDA Ratio | 0.80 | 0.84 | 0.81 | 0.71 | 0.84 | 0.96 |
Debt / FCF Ratio | 1.54 | 1.48 | 1.70 | 1.35 | 1.21 | 1.42 |
Net Debt / Equity Ratio | 0.18 | 0.17 | 0.24 | -0.03 | 0.14 | 0.35 |
Net Debt / EBITDA Ratio | 0.22 | 0.23 | 0.31 | -0.04 | 0.16 | 0.36 |
Net Debt / FCF Ratio | 0.43 | 0.40 | 0.66 | -0.07 | 0.24 | 0.53 |
Asset Turnover | 1.34 | 1.33 | 1.36 | 1.38 | 1.40 | 1.36 |
Inventory Turnover | - | 46.59 | 46.27 | 49.67 | 47.16 | 47.03 |
Quick Ratio | 0.86 | 0.90 | 0.84 | 1.18 | 1.01 | 1.00 |
Current Ratio | 0.94 | 0.97 | 0.95 | 1.28 | 1.09 | 1.06 |
Return on Equity (ROE) | 45.93% | 41.02% | 43.16% | 45.73% | 48.72% | 55.70% |
Return on Assets (ROA) | 16.92% | 16.48% | 17.79% | 19.03% | 18.47% | 19.36% |
Return on Invested Capital (ROIC) | 35.34% | 34.41% | 38.62% | 44.22% | 40.86% | 38.50% |
Return on Capital Employed (ROCE) | 34.30% | 32.60% | 34.40% | 37.50% | 38.50% | 40.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.06% | 5.29% | 8.06% | 9.59% | 10.38% | 7.92% |
FCF Yield | 5.10% | 5.88% | 7.22% | 9.37% | 13.83% | 10.50% |
Dividend Yield | 2.59% | 3.23% | 5.30% | 7.49% | 8.46% | 5.73% |
Payout Ratio | 52.82% | 59.75% | 62.39% | 36.26% | 56.89% | 62.62% |
Buyback Yield / Dilution | 0.04% | -0.08% | 1.85% | - | - | -0.01% |
Total Shareholder Return | 2.63% | 3.15% | 7.15% | 7.49% | 8.46% | 5.72% |